Particularly, the presence of phenotypic diversity precludes the effective treatment of all patients using the same drug and delays translation of clinical trials' results (i.e. the newly developed drugs) to new standard treatment options. In order to increase the success rate of clinical trials, the efficiency of implementation and ultimately the therapy decision making, the concept of precision medicine has been recently adopted to describe the molecular data consolidation to: a) identify biology-driven drug targets and b) develop disease relevant biomarkers to stratify/ sub-group the patients that are likely to respond to the proposed therapy. To practically support the implementation of the biomarkers as stratification tools in clinical trials, several study designs have been suggested including biomarker-orientated pipelines, such as: i) frequentist adaptive designs (e.g. biomarker-strategy design, enrichment-design, biomarker-stratified [3], ii) Bayesian designs (Bayesian adaptive randomised design [4] ) or iii) hybrid Bayesian-frequentist approaches [5] . These biomarkerguided clinical trials open a new perspective for adaptation of the therapeutic intervention based on the specific molecular profiles of individual patients, rather than the conventional therapy decision means, where therapy is mostly guided by the symptoms or the results of the pathological examination [6] .
Generally, all available drugs target proteins. In comparison to the analysis at the level of DNA or RNA, the analysis of the proteins displays more accurately the real-time dynamic cell phenotype, thus proteomics approaches offer an opportunity to identify the best suited biomarkers and drug targets (Figure 1) . Specifically, proteins are the key building blocks of life, retaining a structural, functional and regulatory role, being thus responsible for the orchestration of biological functions. In principle, proteins' function is the result of the genetic This article is protected by copyright. All rights reserved. 5
information that is integrated through alternative splicing, translational and post-translational modifications and further supplemented by environmental factors. Therefore, proteomic changes describe the functional status of organism. Significant changes at the protein level provide information on specific disease-altered pathways, allowing to understand the molecular mechanisms associated with disease. Additionally, through the interpretation of the proteomics data using in silico approaches, proteins that are involved in several pathways and have a causative relationship to the disease initiation and progression, can be revealed. Due to the recent technological advancements in the field of proteomics-including, but not limited to the introduction of the high-resolution mass spectrometry, a global more thorough assessment of the proteins expressed at a certain period of time under specific conditions has become possible. Application of proteomics to analyze clinical specimens such as body fluids or tissue samples (a field also known as clinical proteomics), has recently become a more common approach to address clinically relevant questions and improve on available means for patients' management (e.g. diagnosis, monitoring, therapy) [7] [8] [9] . In this review, we aim at providing an overview of the contribution of proteomics approaches in personalized medicine, by emphasizing on the applicability of proteomics techniques to improve on bladder cancer (BC) management.
B. From proteomics to personalized medicine
To assess the contribution of proteomics in personalized medicine to date, a literature search was conducted using the Web of Science database, as follows: TOPIC: ("proteom*"
AND "personal*") AND TITLE: ("personal*"). Only manuscripts defined as "ARTICLE" OR "REVIEW" types published within the last 5 years (2012 -2017) were considered. By applying the above criteria, a total number of 195 papers were retrieved and further screened independently by the co-authors. Focus was placed on the original research articles that are describing the application of proteomics alone or in combination with other approaches in the context of personalized medicine. To provide an overview of the technological advancements, methodological articles devoted to the development of Proteomics -Clinical Applications This article is protected by copyright. All rights reserved. 6
analytical workflows/ tools in the proteomics field have been also included. Twenty studies ( Supplementary Table 1 ) were selected by at least two co-authors. These are further described in this review, sub-categorized based on the intended context of use, wherever applicable.
i. Health screening and disease prevention
Molecular profiling can support screening, as it can provide with a dynamic assessment of the health and disease state. Continuous monitoring during frequent intervals allows for the detection of a disease prior to its onset or at an early stage, where treatment options are most effective. By employing this concept, Chen et al. established an integrative Personal Omics Profile (iPOP) of one generally healthy Individual (male), who had been monitoredover a period of 14 months [10] . The profile represents a pioneering study in the field of personalized medicine, since the health status of the selected Individual was monitored using multi-dimensional molecular profiling of blood components (including genomic, transcriptomic, proteomic, metabolomics and auto-antibody) across twenty time points.
Through this longitudinal study, a dynamic picture of molecular changes across health and disease status (for example, during the monitoring two episodes of viral infections occurred) was acquired. Importantly, risk assessment based on molecular data indicated a high risk of type-2 diabetes. Subsequent monitoring of the Individual confirmed the development of the disease, supporting the value of molecular profiling to assess disease risk in healthy population [10] . Moreover, in a follow-up study [11] , it has been demonstrated that the level of pathways' differential expression computed based on the previously described iPOP was associated with the disease status, supporting the use of pathway analysis to monitor disease initiation and progression and evaluate therapeutic response [11] .
ii. Prediction of treatment response
Several studies have been published to address the need to improve treatment efficiency through the development of tools to predict drug response, mostly in the context of cancer (e.g. melanoma [12] , lung cancer [13] ) and kidney diseases (IgA nephropathy [14] ). Krepler Proteomics -Clinical Applications This article is protected by copyright. All rights reserved. 7 et al. investigated twelve patients-derived xenograft models from ten BRAF inhibitor progressed melanoma patients [12] . Proteomics analysis revealed activation of mitogenactivated protein kinases (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways, while genomic profiling indicated presence of several mutations that have been previously associated with drug resistance (e.g. NRAS, MEK1, BRAF amplification, and PTEN deletion). Based on these observations, agents targeting the identified resistance mechanisms showed anti-tumour activity, with the most efficient treatment being based on combination of Capmatinib, Encorafenib and Binimetinib [12] . In another study, Kim et al.
developed a framework for the application of proteomics profiling using Reverse-Phase Protein Array to predict drug sensitivity [13] . As a test case, the effect of twenty four drugs was examined in lung cancer cell lines [13] . Based on the proteomics data and the level of drug tolerance, several models were developed to predict drug sensitivity by using an augmented naive Bayes classifier. When considering the performance of the models based on 20 selected proteins, the predictive accuracy was in the range between 87% and 100%. 
iv. Identification of novel drugs/ drug targets
Multidimensional -omics profiling datasets have been applied for the comprehensive characterization of the tumour-related changes, resulting in identification of novel targets for therapeutic intervention. Agren et al. utilized a genome-scale metabolic model (GEM), to identify anti-metabolites (i.e. drugs that are structural analogs to metabolites), which could serve as novel drugs for hepatocellular carcinoma (HCC) [29] . The GEM was reconstructed on the basis of IHC-based profiling data, task-driven Integrative Network Inference for Tissue algorithm and the Human Metabolic Reaction database 2 [29] . Further treatment with antimetabolites of L-carnitine that have not been evaluated so far resulted in the reduction of Proteomics -Clinical Applications This article is protected by copyright. All rights reserved. 10
HepG2 cell viability when comparing to untreated cells. Ding et al. proposed the identification of drug targets through the assessment of protein and mRNA expression of mutated tumour alleles (independently on the mutation frequency) using -omics profiling [30] . Assuming that the altered proteins derived from the mutated alleles can be targeted for therapeutic intervention, proteome profiling, whole-exome sequencing and RNA-sequencing was carried out in a hyper-mutated patient suffering from HCC. Combination of -omics data with functional analysis using Ingenuity software allowed for prioritization of the candidate mutated driver genes (HNF1A, IDH1, FAH, GNMT, and SPTBN1). Three of them were selected and successfully validated using SRM (HNF1A, FAH, SPTBN1) [30] . Along these lines, Brown et al. applied a combination of morphoproteomics, genomics and personalized tumour graft testing in the context of one of the subtypes of Alveolar rhabdomyosarcoma involving a fusion transcript of PAX3-FKHR (FOXO1 gene) [31] . Combination of these data sets unravelled mechanisms associated with the disease, and allowed for the identification of possible therapeutic targets [31] .
C. New methodological concepts
The Paralemmin-3, Adhesion G-protein coupled receptor G1 and others [34] .
Moreover, efforts
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have been undertaken to improve data sharing in scientific community and computational approaches have been developed to support the -omics data cross-correlation. It has to be underscored that, although several public repositories for storage of the -omics data are available, such as PRIDE PRoteomics IDEntifications [35] , PeptideAtlas [36] (for proteomics data), ArrayExpress [37] , Gene Expression Omnibus [38] (for microarray data),
MetaboLights [39] (for metabolomics data), they are mostly dedicated to the storage and handling of individual -omics traits. Recently, Bauer et al. developed a web-based tool called "BioMiner", which provides access to high-throughput cancer-related -omics datasets as well as to an analytical toolbox designed for multi-omics data analysis [40] . Furthermore, algorithms supporting the analysis and visualization of treatment response data have been presented. Bouwman et al. described a statistics-based visualization method (called "health space") on the basis of the pre-selected biological processes defined through the analysis of -omics data sets (i.e. proteomics, transcriptomics, metabolomics) [41] . This methodology was applied to describe an effect of the nutritional intervention in a group of 36 subjects, allowing for the discrimination of treated and untreated individuals as well as assessment of the biological processes modulated in these groups [41] .
D. Personalized medicine in Bladder Cancer
The need for developing precision medicine is rising given that patient response rates to the drugs reach only 25% efficiency in cancer [42] . There appears to be no study yet demonstrating the successful application of either proteomics or other -omics technology in personalized medicine. However, as outlined in the course of recently published review articles [43] [44] [45] , substantial progress has been made towards the identification of proteomics-derived biomarkers as well as putative targets for therapeutic intervention to support patient management (diagnosis, monitoring, stratification and treatment) in bladder cancer. Urothelial carcinoma or bladder cancer is a disease, where personalized medicine seems ideally suited to improve on its management, given: a) the epidemiological and clinical facts, b) the intrinsic heterogeneity of the disease and thus, c) the lack of effective treatment. Therefore, in the This article is protected by copyright. All rights reserved. 12 subsequent part of this manuscript, a critical assessment of the current status of proteomics developments in the field of bladder cancer personalized medicine is presented.
i. Epidemiological/ clinical facts
Bladder Cancer is the second most common cancer of the genitourinary tract, the 4 th most common cancer in men and the 11 th most common in women [46] . [47] ). So far, no alternative non-invasive tool to replace cystoscopy is accepted in the guidelines [47] . Considering this fact, development of non-invasive tools to guide cystoscopy and reduce its frequency during the follow-up monitoring of BC is expected to improve BC patient management. Implementation of such biomarkers would have a significant impact on the patient management, e.g. through guidance of cystoscopy (Figure 2) . Negative results of the test would allow avoiding unnecessary cystoscopy, while positive result could increase urologist alertness to perform more thorough examination. For patients that are at risk for This article is protected by copyright. All rights reserved. 13
disease recurrence and undergo frequent monitoring, application of the non-invasive test would decrease the number of invasive cystoscopies. Considering that biomarker tests cannot reach ultimate sensitivity levels (100%), misclassification of some patients will occur, but this is also observed in cystoscopy. Further, due to the frequent follow-up, particularly during surveillance (which for high risk cases, examination every three months is suggested), it is expected that misdiagnosed tumours will be correctly detected later during the follow-up.
ii. Addressing disease heterogeneity
Molecular profiling data revealed that bladder cancer is a highly heterogeneous disease. The classical classification is based on two pathologically distinct progression forms, called papillary and non-papillary [52, 53] . The currently available data suggest that papillary BC (stratified as NMIBCs) evolves from hyperplasia of the urothelium through disruption on the phosphatidylinositol-3-kinase/ Akt and the mammalian target of rapamycin (PI3K-AKT-mTOR), Fibroblast growth factor receptor 3 and GTPase HRas [54] pathways, while nonpapillary expansion (clinically stratified as MIBC) evolves through urothelial dysplasia and carcinoma in situ caused by alterations in TP53, CDKN2A, CCND1, CDKN1B and RB1 [54] .
Molecular characterization at the genetic level based on next generation sequencing data [55] [56] [57] [58] [59] , suggested a new sub-classification involving of NMIBC and MIBC, based on mutation status of epithelial cytokeratins HIF-1, EGFR, FGFR, ERB as well as PI-3 kinase/AKT pathway [60] . The presence of additional molecular disease subtypes has been suggested by various groups (as summarized in [61, 62] ) nevertheless, with a consensus on clinical decision making not having been reached yet. Due to the increased BC heterogeneity and as the individual molecular profile has a significant impact on disease aggressiveness and drug response, therapeutic decision making based on the classical histopathological assessment of the tumour tissue is not always successful. A detailed investigation of the molecular alterations underlying BC appears to present an ideal basis for the establishment of personalized therapeutic interventions [56, 63] . This could possibly also This article is protected by copyright. All rights reserved. 14 decrease the economic burden of bladder cancer: lifetime treatment costs per patients are the highest among all cancer types [64] . This is also evident based on the estimates for the BC related health care costs for year 2012, reaching up to €2.87 billion in 2012, which accounts for 5% of the total cancer health expenditure) [65] . While reliable biomarkers for patient stratification are currently not available for clinical use, the newly designed clinical trials highlight the value of companion tests, like prognostic and predictive biomarkers and stratification tools to guide intervention [56, 66, 67] .
iii. Proteomics to support personalized medicine in BC
As shown above, the application of clinical proteomics represents a promising strategy to address the challenges related to BC patients' management. For that purpose, a broad range of biological specimens, that best reflect molecular changes associated with the pathological condition, was investigated using different proteomics platforms. In the context of BC, the main research focus has been placed on the assessment of urine and tissue proteome (Figure 2) . Through the direct contact with the bladder tumour, the urinary proteome is expected to be enriched in proteins reflecting the tumour development and invasion. Moreover, urine can be obtained non-invasively, shows increased stability over serum/ blood and it allows for easy multiple sampling. Investigation of the urinary proteome has been mostly applied for identifying non-invasive biomarkers for diagnosis of primary and recurrent BC as well as assessment of disease-aggressiveness.
Although urine proteome analysis enables the identification of biomarkers, it generally does not provide a direct link to the disease pathophysiology. This can be achieved, though, by tissue proteomics, since tissue represents a direct site of disease initiation and progression.
Tissue proteomics can provide insights into disease-associated mechanisms, thus identify best suited biology-driven therapeutic targets. Collectively, urinary proteome profiling can be used to support personalized disease diagnosis/ monitoring and stratification; while tissue proteomics can address the concept of personalised therapeutic intervention, through identification of novel therapeutic targets (Figure 3) . In the following sub-sections, an
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overview on the proteomics studies addressing the above mentioned clinical applications using the state-of-the-art MS-based platforms is given.
-Diagnosis and monitoring of bladder cancer
Up to now, several urinary biomarkers have been described, among others the FDA approved immunoassays, which measure the urinary levels of Bladder cancer associated mainly assessed by immunoassays (ELISA). However, several limitations, involving lack of appropriate diseased matched controls in the studies, as well as difficulties related to the analytical validation of ELISA urine based assays [70] , shifts the research focus towards the application of mass spectrometry based platforms for the development of clinically useful biomarkers. Particularly Multiple reaction monitoring (MRM) [71] and CE-MS [24, 26, [72] [73] [74] are two mass spectrometry based platforms that can support well powered validation studies and are proven to be applicable in clinical practice.
In bladder cancer, MRM has been applied to validate previously reported biomarkers, among In parallel, CE-MS based urinary proteome analysis has been applied in the context of BC, as reported [73, 77, 78] , aiming at: 1) discovering diagnostic biomarkers that enable detection of BC [78] , 2) validating discriminatory biomarkers to sub-classify between nonmuscle and muscle invasive disease [77] and 3) detecting primary and recurrent BC in clinical settings [73] . The above studies are summarised in Table 1 . The first study was performed by Theodorescu et al. in 2006 [78] , where a panel of 22 urinary biomarkers was established in a small cohort of BC patients and healthy individuals (N = 121) [78] . Validation in independent samples (31 patients with BC and 366 controls) resulted in 100% sensitivity and 73% specificity [78] . Even though the performance of this biomarker panel provides a good discriminatory accuracy for detection of advanced BC in the general population, the performance was limited when the classification of less advanced cases was attempted. To address this issue, in a study by Schiffer et al. [77] , a biomarker panel comprised of 4 urinary peptides was established to differentiate between patients with NMIBC and MIBC. Further inclusion of the tumour grade increased the discriminatory capability and resulted in the sensitivity of 92% and specificity of 68% [77] . As a follow-up of these studies, a large multicentric study (including 5 clinical centres from Europe and USA, n = 1357) was designed, with the experimental set-up reflecting well the clinical situation [73] . In this study, two multimarker panels comprised of 116 and 106 urinary peptides were established for the purpose of detecting primary (n = 721) and recurrent bladder cancer (n = 636), respectively, resulting This article is protected by copyright. All rights reserved. 17
in AUCs of 0.87 and 0.75, respectively [73] . Among the peptide biomarkers that are included in the CE-MS panel are several Fibrinogen chains, Apolipoprotein A1, Beta-2-macroglobulin and Basement membrane-specific heparan sulfate proteoglycan, that have also been described as single protein biomarkers in BC proteomics studies [44] . In the above investigation the urinary profiling data also reflected disease progression, as displayed in Figure 4 . Further, a significant correlation of peptide abundance with disease stage and grade was reported [73] .
-
Patient stratification
Although a study demonstrating a clear value of proteomics biomarkers as stratification tools has not been published yet, initial data indicate substantial value and support the idea of using proteomics for patient stratification. So far, the main aim in the investigation of proteins in the context of BC progression involved the correlation of tissue expressed protein biomarkers with the disease outcome. As such, the vast majority of the tissue proteomics studies involved single biomarkers investigated by immunohistochemistry (IHC) and tissue
microarrays. An overview of such tissue biomarker studies in BC was recently published [44] . In brief, proteins like Cystatin B, extracellular matrix and cytoskeletal related proteins (Actin, Desmin, Vimentin, Annexin, Profilin-1) and others like Histone 2B, bladder cancerassociated protein (BLCAP) and p54 were reported to be significantly associated with BC.
Although promising, these biomarkers cannot serve as non-invasive prognostic/ stratification tool and provide limited information on the affected molecular pathways. Urinary biomarker panels seem to be better suited in guiding personalized intervention. As described in the study by Frantzi et al. [73] , CE-MS urinary profiling data can reflect disease progression to MIBC, indicated by the gradual change in the abundance of the urinary peptides along with cancer progression [73] . Preliminary results support the use of urinary peptide profiling as a tool for non-invasive patient stratification, as patients with a positive scoring for urinary based-test have significantly lower survival probability than patients with negative scores, at the defined endpoint which was the time to disease relapse (Belczacka, Frantzi et al., This article is protected by copyright. All rights reserved. 18
unpublished data). Therefore, a study investigating the benefits of urinary proteome-guided personalized intervention seems warranted, to investigate the potential value of urinary profiling for patient stratification by enabling earlier intervention and consequently improved survival and quality of life.
Identification of novel drugs/ drug targets
Mass spectrometry based tissue proteomics was applied initially aiming towards a better understanding of disease-associated molecular pathophysiology. First studies have been published aiming at increasing our knowledge for the disease related proteins and associated pathways and have been recently reviewed in [43, 44] . Initially, no clear indication for potential drug targets was reported. This concept, however, was recently In a further advancement, a study investigating a total of 11 tissue samples was published, aiming at detecting differences in the proteome profile between NMIBC (n = 5, stage pTa) and MIBC (n = 6, stages pT2+). Using high-resolution LC-MS/MS [80] , 144 proteins associated with cancer invasion were identified, including multiple proteins previously linked to BC including but not limited to some Annexins, Alpha actinins, Cathepsin E, Hydroxyprostaglandin dehydrogenase 15-(NAD), Thymidine phosphorylase and others.
Importantly, through the in silico analysis, Eukaryotic translation initiation factor 3 subunit D was identified as a promising target for intervention (up-regulated in MIBC vs NMIBC), and This article is protected by copyright. All rights reserved. 19
its functional relevance was investigated using in vitro and in vivo disease models [80] .
Specifically, it has been demonstrated that stable knockdown of EIF3D using lentivirusmediated RNA interference in a metastatic BC cell line (T24M) resulted in decreased cell proliferation, migration capacity and colony formation. Subsequent investigation in xenograft models showed a decrease in the tumour growth. These recent studies highlight the potential of the use of tissue proteomics based approach to identify new drug targets for bladder cancer.
Proteome analysis has been applied to investigate effect and molecular mechanisms of novel potential drugs for BC. Li et al. [81] assessed the effect of five HSP90 inhibitors (AUY922, ganetespib, SNX2112, AT13387, and CUDC305) in vitro using the 5637 urinary bladder cancer 
iv. Health economic aspects
Considering the emerging need on improving the BC patient management, studies assessing the cost-effectiveness of bladder cancer biomarkers have been published, mainly including the comparative investigations of the FDA approved urinary biomarkers [fluorescence in situ hybridisation (FISH), ImmunoCyt, NMP22] and cytology with the current diagnostic standard, which is cystoscopy [68, 82] . For the above economic evaluations, the decision model included the biomarker tests and cytology, as means to guide cystoscopy. As such, the positive result of This article is protected by copyright. All rights reserved. 20
the biomarker/cytology test should be further confirmed with cystoscopy, while true negative results will not warrant further investigation. According to the results the application of Immmunocyt (with estimated pooled sensitivity of 84% and specificity of 75%), followed by cystoscopy, was the most cost-effective strategy [68] . Regarding the proteomic derived biomarkers, a health economic evaluation was performed based on the results of the CE-MS based biomarker panels [43] , in the context of TransBioBC European project (Project ID: 601933). The results indicated that a test at cost <600€, which is not higher than the costs associated with white light cystoscopy would be cost effective, in guiding the cystoscopic procedures. In particular, the decrease in the number of unnecessary cystoscopies (resulting from the use of the urinary based CE-MS biomarkers) is expected to decrease the disease associated costs.
E. Outlook
Based on the evidence accumulated over the last five years and driven by advancements in the proteomics workflows, computational tools and applicability of -omics data cross-correlation, employing proteome analysis to support personalized medicine now becomes feasible. The approach is expected to improve personalized healthcare through the better assessment of the disease risk, more accurate diagnosis and disease monitoring and also targeted treatment.
However, the level of evidence supporting the feasibility of the translation of individualized molecular profiles into routine application is still quite moderate. Specifically, limited statistical power and lack of proper validation conducted in large independent sets of samples are main points that still remain to be addressed. The most effective approach in this respect appears to be the investigation of multiple approaches in parallel in the same population, as suggested recently [83] . Moreover, better computational approaches are required to further support the transfer of the personalized medicine into clinical routine.
Regarding BC and the need for biology-driven drug targets, several studies demonstrate the value of tissue proteomics profiling. Moreover, extensive research conducted has enabled discovery and validation of diagnostic and prognostic proteomic biomarkers for bladder cancer.
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However, the use of state-of-the-art proteomics approaches for assessment of treatment response or patients' stratification remains to be addressed. Given the complexity of action of the drugs, a rational prediction of proteins related to drug response does not appear suitable using a single marker test. Therefore, the most credible approach appears to be the This article is protected by copyright. All rights reserved. 36 This article is protected by copyright. All rights reserved. 37 representation of the potential use of proteomics-based molecular profiles of urine and tissue is provided. In actual application, classifiers to predict the response to the known drugs are expected to be applied, in order to provide a score depicting the likelihood of response to the respective drug. Consequently, the drug with highest scoring will be chosen for therapy, to increase the success rate of the therapy. In the next step, classifiers to predict the disease progression and also monitor the treatment effect in a non-invasive way are applied. In case of a positive result for disease progression, alternative/ more efficient treatment will be then selected. Abbreviations: BC -Bladder Cancer. Supplementary Table 1 . List of the 20 relevant manuscripts in the context of proteomics and personalized medicine retrieved from the literature mining.
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